Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
| Autor: | Nath K; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Wudhikarn K; Division of Hematology and Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Alarcon Tomas A; Division of Hematology and Hemotherapy, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Perales MA; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Expert opinion on drug safety [Expert Opin Drug Saf] 2023 Jan; Vol. 22 (1), pp. 5-15. Date of Electronic Publication: 2023 Feb 17. |
| DOI: | 10.1080/14740338.2023.2177268 |
| Abstrakt: | Introduction: CD19-directed chimeric antigen receptor (CAR) T-cell therapy is a highly effective therapy for patients with relapsed/refractory large B-cell lymphoma (LBCL) and three CD19 CAR T-cell products (axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel) are currently approved for this indication. Despite the clinical benefit of CD19 directed CAR T-cell therapy, this treatment is associated with significant morbidity from treatment-emergent toxicities. Areas Covered: This Review discusses the safety considerations of axicabtagene ciloleucel in patients with LBCL. This includes discussion of the frequently observed immune-mediated toxicities of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Additionally, we review CAR T-cell therapy related cytopenias, infection, organ dysfunction and the more recently described hemophagocytic lymphohistiocytosis. Expert Opinion: A thorough understanding of the toxicities associated with CD19-directed CAR T-cell therapy will facilitate the optimal selection of patients for this therapy. Furthermore, knowledge of preventative measures of CAR T-cell related complications, and early recognition and appropriate intervention will lead to the safe administration of these therapies, and ultimately improved outcomes for our patients. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|